UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

BMC cancer, 2019-02, Vol.19 (1), p.184-184, Article 184

2019

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

The New England journal of medicine, 2015-03, Vol.372 (10), p.944-953

2015

Link zum Volltext

Verfügbarkeit prüfen

Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand

PloS one, 2019-03, Vol.14 (3), p.e0214148-e0214148

2019

Link zum Volltext

Verfügbarkeit prüfen

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines

Scientific reports, 2021-06, Vol.11 (1), p.13283-13283, Article 13283

2021

Link zum Volltext

Verfügbarkeit prüfen

Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand

Supportive care in cancer, 2021-11, Vol.29 (11), p.6511-6522

2021

Link zum Volltext

Verfügbarkeit prüfen

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience

Annals of hematology, 2018-06, Vol.97 (6), p.1019-1026

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

The lancet oncology, 2014-03, Vol.15 (3), p.343-352

2014

Link zum Volltext

Verfügbarkeit prüfen

Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients

Annals of hematology, 2021-04, Vol.100 (4), p.891-901

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study

American journal of hematology, 2014-07, Vol.89 (7), p.751-756

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

The Lancet. Haematology, 2017-06, Vol.4 (6), p.e272-e282

2017

Link zum Volltext

Verfügbarkeit prüfen

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study

Leukemia & lymphoma, 2019-01, Vol.60 (1), p.172-179

2019

Link zum Volltext

Verfügbarkeit prüfen

Glutathione Redox System in β-Thalassemia/Hb E Patients

TheScientificWorld, 2013-01, Vol.2013, p.543973-7

2013

Link zum Volltext

Verfügbarkeit prüfen

A prospective analysis for prevalence of complications in Thai nontransfusion‐dependent Hb E/β‐thalassemia and α‐thalassemia (Hb H disease)

American journal of hematology, 2018-05, Vol.93 (5), p.623-629

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological Characteristics of Subcutaneous Panniculitis-like T-Cell Lymphoma in Asian Population: A Retrospective Cohort of 48 Patients

Blood, 2021-11, Vol.138 (Supplement 1), p.4544-4544

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Blood, 2018-01, Vol.131 (2), p.263-265

2018

Link zum Volltext

Verfügbarkeit prüfen

An Urgent Need for Improving Thalassemia Care in Adult Patients Due to a Wide Gap on Current Real-Life Practice and Recommended Clinical Practice Guidelines

Blood, 2017-12, Vol.130 (Suppl_1), p.952-952

2017

Link zum Volltext

Verfügbarkeit prüfen

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

The lancet oncology, 2014-10, Vol.15 (11), p.1195-1206

2014

Link zum Volltext

Verfügbarkeit prüfen

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

The lancet oncology, 2018-11, Vol.19 (11), p.1449-1458

2018

Link zum Volltext

Verfügbarkeit prüfen

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Blood, 2012-08, Vol.120 (5), p.970-977

2012

Link zum Volltext

Verfügbarkeit prüfen

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Blood, 2014-03, Vol.123 (10), p.1447-1454

2014

Link zum Volltext

Verfügbarkeit prüfen

An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results

American journal of hematology, 2022-08, Vol.97 (8), p.E281-E284

2022

Link zum Volltext

Verfügbarkeit prüfen

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

British journal of haematology, 2015-01, Vol.168 (2), p.284-290

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(88)
Berichte
(1)

Sprache

Englisch
(89)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(52)
Science & Technology
(52)
Life Sciences & Biomedicine
(48)
Hematology
(39)
Male
(39)
Female
(37)
Adult
(35)
Middle Aged
(26)
Adolescent
(16)
Aged
(16)
Young Adult
(14)
Oncology
(13)
Thalassemia
(13)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Treatment Outcome
(11)
Blood Transfusion
(10)
Iron Overload - Drug Therapy
(9)
Medicine
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines

Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Whole exome sequencing and rare variant association study to identify genetic modifiers, KLF1 mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study

Glutathione Redox System in β-Thalassemia/Hb E Patients

A prospective analysis for prevalence of complications in Thai nontransfusion‐dependent Hb E/β‐thalassemia and α‐thalassemia (Hb H disease)

Clinicopathological Characteristics of Subcutaneous Panniculitis-like T-Cell Lymphoma in Asian Population: A Retrospective Cohort of 48 Patients

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

An Urgent Need for Improving Thalassemia Care in Adult Patients Due to a Wide Gap on Current Real-Life Practice and Recommended Clinical Practice Guidelines

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

Suchergebnisse filtern